Elon Musk’s Neuralink Chip Has Malfunctioned In Its First In-Human Brain Implant

According to reports on Wednesday, Neuralink, Elon Musk’s brain-chip startup, experienced an unanticipated failure during its first human implant. Data capture was impacted by the device’s separation from the patient’s skull during the event.

With patient Noland Arbaugh’s implant, Neuralink’s groundbreaking brain-computer interface (BCI) technology seeks to enable people with paralysis to manipulate external equipment with mental commands. After a diving accident left him paralysed from the shoulders down, Arbaugh took part in Neuralink’s six-year experiment to evaluate the device’s effectiveness and safety.

Arbaugh recently performed a live demonstration of the BCI’s capabilities, using neural impulses to control a cursor in a video game. With 1,024 electrodes spread across 64 threads, the chip makes it easier to gather information on cerebral activity that can be translated into valuable commands.

Neuralink, however, disclosed a troubling development after the demonstration: “Several threads retracted from [Arbaugh’s] brain,” resulting in reduced electrode performance. This setback forced the company to improve signal translation methods and the recording algorithm to boost performance metrics like bits per second (BPS), which is a crucial indicator of accuracy and speed in BCI systems.

Though there were discussions about removing the implant, which was considered an “explanation,” Neuralink guaranteed Arbaugh’s safety. In the face of legal troubles, the company moved from Delaware to Nevada, demonstrating its dedication to innovation in the face of difficulties.

Thankfully, Neuralink declared that the chip was back in working order, and Arbaugh showed better BPS performance after the change. Arbaugh’s commitment to the trial, including utilising the BCI system for hours daily, indicates his hope for the device’s revolutionary potential.

Neuralink’s journey, once veiled in secrecy, has drawn interest and demands for increased transparency. Despite opposition from animal rights organisations, the FDA approved human trials after conducting extensive animal research. Overcoming challenges like electrode detachment highlights the difficulties of pioneering neuroscience endeavours as the company continues its goal to unite the human mind with technology.